

Drug	Schedule	Drug	Schedule
N-Hydroxy-3,4-methylenedioxyamphetamine (7402).	I	Opium fluid extract (9620)	II
Nicocodeine (9309)	I	Opium tincture (9630)	II
Nicomorphine (9312)	I	Opium, granulated (9640)	II
N-Methyl-3-piperidyl benzilate (7484).	I	Oxycodone (9143)	II
Noracymethadol (9633)	I	Oxymorphone (9652)	II
Norlevorphanol (9634)	I	Pentobarbital (2270)	II
Normethadone (9635)	I	Phenazocine (9715)	II
Normorphine (9313)	I	Phencyclidine (7471)	II
Norpipanone (9636)	I	Phenmetrazine (1631)	II
Para-Fluorofentanyl (9812)	I	Phenylacetone (8501)	II
Parahexyl (7374)	I	Piminodine (9730)	II
Peyote (7415)	I	Powdered opium (9639)	II
Phenadoxone (9637)	I	Racemorphan (9732)	II
Phenampromide (9638)	I	Racemorphan (9733)	II
Phenomorphane (9647)	I	Remifentanyl (9739)	II
Phenoperidine (9641)	I	Secobarbital (2315)	II
Pholcodine (9314)	I	Sufentanil (9740)	II
Piritramide (9642)	I	Thebaine (9333)	II
Proheptazine (9643)	I		
Propofol (9644)	I		
Propiram (9649)	I		
Psilocybin (7437)	I		
Psilocyn (7438)	I		
Racemoramide (9645)	I		
Tetrahydrocannabinols (7370)	I		
Thebacon (9315)	I		
Thiofentanyl (9835)	I		
Tilidine (9750)	I		
Trimeperidine (9646)	I		
1-Phenylcyclohexylamine (7460) ..	II		
1-Piperidinocyclohexanecarbonitrile (8603).	II		
Alfentanil (9737)	II		
Alphaprodine (9010)	II		
Amobarbital (2125)	II		
Amphetamine (1100)	II		
Anileridine (9020)	II		
Bezitramide (9800)	II		
Carfentanyl (9743)	II		
Codeine (9050)	II		
Dextropropoxyphene, bulk (non-dosage forms) (9273).	II		
Dihydrocodeine (9120)	II		
Dihydroetorphine (9334)	II		
Diphenoxylate (9170)	II		
Ethylmorphine (9190)	II		
Etorphine Hcl (9059)	II		
Fentanyl (9801)	II		
Glutethimide (2550)	II		
Hydrocodone (9193)	II		
Hydromorphone (9150)	II		
Isomethadone (9226)	II		
Levo-alphaacetylmethadol (9648) ..	II		
Levomethorphan (9210)	II		
Levorphanol (9220)	II		
Lisdexamfetamine (1205)	II		
Meperidine (9230)	II		
Meperidine intermediate-A (9232) ..	II		
Meperidine intermediate-B (9233) ..	II		
Meperidine intermediate-C (9234) ..	II		
Metazocine (9240)	II		
Methadone (9250)	II		
Methadone intermediate (9254) ..	II		
Methamphetamine (1105)	II		
Methylphenidate (1724)	II		
Metopon (9260)	II		
Moramide intermediate (9802)	II		
Morphine (9300)	II		
Nabilone (7379)	II		
Opium, raw (9600)	II		
Opium extracts (9610)	II		

The company plans to import small quantities of the listed controlled substances for the National Institute on Drug Abuse (NIDA) for research activities.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Research Triangle Institute to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Research Triangle Institute to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: July 29, 2008.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E8-17966 Filed 8-5-08; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated March 19, 2008 and published in the **Federal Register** on March 28, 2008, (73 FR 16719), Sigma

Aldrich Research Biochemicals, Inc., 4-3 Strathmore Road, Natick, Massachusetts 01760-2447, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Cathinone (1235)	I
Methcathinone (1237)	I
Aminorex (1585)	I
Alpha-ethyltryptamine (7249)	I
Lysergic acid diethylamide (7315)	I
Tetrahydrocannabinols (7370)	I
4-Bromo-2,5-dimethoxyamphetamine (7391).	I
4-Bromo-2,5-dimethoxyphenethylamine (7392).	I
2,5-Dimethoxyamphetamine (7396).	I
3,4-Methylenedioxyamphetamine (7400).	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402).	I
3,4-Methylenedioxy-N-ethylamphetamine (7404).	I
3,4-Methylenedioxy-methamphetamine (MDMA) (7405).	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470).	I
1-Benzylpiperazine (BZP) (7493)	I
Heroin (9200)	I
Normorphine (9313)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Nabilone (7379)	II
1-Phenylcyclohexylamine (7460)	II
Phencyclidine (7471)	II
Cocaine (9041)	II
Codeine (9050)	II
Diprenorphine (9058)	II
Ecgonine (9180)	II
Levomethorphan (9210)	II
Levorphanol (9220)	II
Meperidine (9230)	II
Metazocine (9240)	II
Methadone (9250)	II
Morphine (9300)	II
Thebaine (9333)	II
Levo-alphaacetylmethadol (9648) ..	II
Carfentanyl (9743)	II
Fentanyl (9801)	II

The company plans to manufacture reference standards.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Sigma Aldrich Research Biochemicals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Sigma Aldrich Research Biochemicals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical

security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: July 30, 2008.

Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E8-18065 Filed 8-5-08; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 3, 2008, Chemic Laboratories, Inc., 480 Neponset Street, Building 7, Canton, Massachusetts 02021, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II.

The company plans to manufacture small quantities of the above listed controlled substance for distribution to its customers for the purpose of research.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008.

Dated: July 28, 2008.

Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E8-17955 Filed 8-5-08; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 28, 2008, Chattem Chemicals Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Table with 2 columns: Drug, Schedule. Lists various controlled substances like 4-Methoxyamphetamine, Difenoxin, Amphetamine, etc., with their corresponding schedules.

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008.

Dated: July 29, 2008.

Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E8-17961 Filed 8-5-08; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 3, 2008, Cambridge Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of Morphine (9300), a basic class of controlled substance listed in schedule II.

The company plans to utilize small quantities of the listed controlled substance in the preparation of analytical standards.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008.

Dated: July 29, 2008.

Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E8-17962 Filed 8-5-08; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 28, 2008, Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedule II:

Table with 2 columns: Drug, Schedule. Lists Amphetamine (1100), Lisdexamfetamine (1205), Methylphenidate (1724), Methadone (9250) with their corresponding schedules.